Companies
Inari
SEEDesign™ platform — Multiplex gene editing.
- Country
- United States
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| crop-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisepaefsamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $579M total funding across 4 to 8 rounds | getlatka.com |
| Headcount | 590 employees (as of 2026) | getlatka.com |
| Revenue | $144.5M annual revenue (estimated 2024 ARR) | getlatka.com |
| Regulatory approval | USDA determined modified wheat and soybean lines are not regulated under 7 CFR part 340 (2025) | direct.aphis.usda.gov |
| Production site | Cambridge, MA (HQ); West Lafayette, IN; Ghent, Belgium | inari.com · ptacts.uspto.gov |
| Capacity | Expanded facility in West Lafayette includes more than double the site’s previous greenhouse space | inari.com |
Independent sources: direct.aphis.usda.gov · getlatka.com · ptacts.uspto.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Genetic engineering & bio-selection | crop-biotech | No data | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.